标题
Antibodies to watch in 2023
作者
关键词
-
出版物
mAbs
Volume 15, Issue 1, Pages -
出版商
Informa UK Limited
发表日期
2022-12-06
DOI
10.1080/19420862.2022.2153410
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- (2022) Jeffrey S Heier et al. LANCET
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- (2022) Charles C Wykoff et al. LANCET
- Antibodies to watch in 2022
- (2022) Hélène Kaplon et al. mAbs
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy
- (2022) Samer K. Khaled et al. JOURNAL OF CLINICAL ONCOLOGY
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
- (2022) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2022) Jie Wang et al. LANCET ONCOLOGY
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
- (2022) Laura L. Hammitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
- (2022) Joseph Domachowske et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models
- (2022) Li-li zhai et al. Travel Medicine and Infectious Disease
- Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
- (2022) Rajat Bannerji et al. Lancet Haematology
- Sutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial
- (2022) Alexander Röth et al. BLOOD
- Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
- (2022) Yuankai Shi et al. HEMATOLOGICAL ONCOLOGY
- GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).
- (2022) Huiqiang Huang et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of the anti–PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study.
- (2022) Jusheng An et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2022) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II / III results of the anti‐TNF multivalent NANOBODY ® compound ‘ozoralizumab’ in patient with rheumatoid arthritis ( OHZORA trial)
- (2022) Tsutomu Takeuchi et al. Arthritis & Rheumatology
- Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
- (2022) Hugh Montgomery et al. Lancet Respiratory Medicine
- Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events
- (2022) Zhaoliang Huang et al. Frontiers in Immunology
- Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors
- (2022) Xu Liang et al. Frontiers in Oncology
- Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects
- (2022) Junnan Zhang et al. Vaccines
- HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
- (2022) Josep Tabernero et al. Future Oncology
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
- (2022) Ying Cheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names
- (2022) Ian Wilkinson et al. mAbs
- The On- and Off-Ramps of Oncology Accelerated Approval
- (2022) Lola A. Fashoyin-Aje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
- (2022) Lawrence Steinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
- (2022) Sergey Shcherbinin et al. JAMA Neurology
- POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma
- (2022) Sheela Rao et al. Frontiers in Oncology
- Antibodies to watch in 2021
- (2021) Hélène Kaplon et al. mAbs
- Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
- (2021) Jie Wang et al. JAMA Oncology
- Efficacy and safety of JMT103 in patients with giant cell tumor of bone: A multicenter, single-arm, open-label, phase Ib/II study.
- (2021) Xiaohui Niu et al. JOURNAL OF CLINICAL ONCOLOGY
- Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
- (2021) Shun Lu et al. Journal of Thoracic Oncology
- Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
- (2021) Martin Hutchings et al. LANCET
- Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
- (2021) Hai-Qiang Mai et al. NATURE MEDICINE
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II randomized, double-blind, placebo-controlled study
- (2021) Jing Li et al. RHEUMATOLOGY
- Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies
- (2021) K. Kabashima et al. BRITISH JOURNAL OF DERMATOLOGY
- A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab
- (2021) Andrew McKenzie et al. CTS-Clinical and Translational Science
- Trial of Spesolimab for Generalized Pustular Psoriasis
- (2021) Hervé Bachelez et al. NEW ENGLAND JOURNAL OF MEDICINE
- HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
- (2020) Jibin Zhang et al. mAbs
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
- (2018) Zenjiro Sampei et al. PLoS One
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Antibodies to watch in 2016
- (2015) Janice M. Reichert mAbs
- Antibodies to watch in 2015
- (2014) Janice M Reichert mAbs
- Antibodies to watch in 2014
- (2013) Janice M Reichert mAbs
- Which are the antibodies to watch in 2013?
- (2013) Janice M. Reichert mAbs
- Which are the antibodies to watch in 2012?
- (2012) Janice M. Reichert mAbs
- Antibody-based therapeutics to watch in 2011
- (2011) Janice M. Reichert mAbs
- Antibodies to watch in 2010
- (2010) Janice M. Reichert mAbs
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started